We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
In our new Industry Voice video podcast episode, join OCT Clinical in discussing the future of chronic metabolic diseases alongside QL Biopharm, a pioneering drug manufacturing company from China. Discover the cutting-edge insights and innovative strategies that QL Biopharm brings to the table, aiming to transform the landscape of chronic metabolic diseases and pharma market in China and around the globe.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
